Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RARα transcripts with a sensitive competitive RT-PCR method

Leukemia

Volumn 15, Issue 7, 2001, Pages 1060-1065

  Tobal, K ^a   Moore, H ^a   Macheta, M ^a   Liu Yin, J A ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

APL; Competitive RT PCR; Minimal residual disease; PML RAR ; t(15; 17)

Indexed keywords

RECEPTOR SUBTYPE; RETINOIC ACID RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BLOOD SAMPLING; BONE MARROW; CANCER RECURRENCE; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CLINICAL ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE FUSION; GENETIC TRANSCRIPTION; HIGH RISK PATIENT; HUMAN; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0034900375     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402170     Document Type: Article

References (25)

1. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia
2. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus
3. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML
4. Genomic variability and alternative splicing generate multiple PML-RARA transcripts that encode aberrant PML proteins and PML-RARA isoforms in acute promyelocytic leukemia
5. Diagnosis of acute promyelocytic leukaemia by RT-PCR: Detection of PML-RARA and RARA-PML fusion transcripts
6. Persistence of RARα-PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukaemia
7. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia
8. Detection of minimal residual disease in acute promyelocytic leukemia by reverse transcriptase polymerase chain reaction assay for PML-RARα fusion mRNA
9. Reverse transcription-polymerase chain reaction for PML-RAR alpha fusion transcripts in acute promyelocytic leukemia and its application to minimal residual leukemia detection
10. Acute promyelocytic leukemia: Clinical relevance of two major PML-RARα isoforms and detection of minimal residual disease by retrotranscriptase
11. Rapid achievement of PML-RAR alpha polymerase chain reaction (PCR) negativity by combined treatment with all-trans retinoic acid and chemotherapy in acute promyelocytic leukemia: A pilot study
12. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: Evaluation of PML-RARα and RARα-PML assessment in patients who ultimately relapse
13. Relapse of acute promyelocytic leukemia follows serial negative RT-PCR assays: A cautionary tale
14. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8;21)
15. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR
16. Detection of minimal residual disease (MRD) in APL by 'real-time' RT-PCR: Analysis of cases entered into the UK MRC ATRA trial
17. Proposed revised criteria for the classification of the acute myeloid leukemia
18. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
19. Molecular quantitation of minimal residual disease in acute myeloid leukaemia with t(8;21) can identify patients in durable remission and predict clinical relapse
20. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: Correlations with acute graft-versus-host disease and relapse
21. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3)
22. RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission of APL
23. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter 'AIDA' trial
24. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the randomized MRC trial
25. Therapy of molecular relapse in acute promyelocytic leukemia